Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease

Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey

(2011) Joseph Muenzer et al.   GENETICS IN MEDICINE

Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II

(2010) A Friso et al.   BRITISH JOURNAL OF PHARMACOLOGY

Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey

(2010) Nancy J. Mendelsohn et al.   GENETICS IN MEDICINE

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

(2010) Joseph Muenzer et al.   GENETICS IN MEDICINE

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

(2010) Kia Jane Langford-Smith et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II

(2010) G. Schulze-Frenking et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II — data from the Hunter Outcome Survey

(2010) Barbara K. Burton et al.   MOLECULAR GENETICS AND METABOLISM

IDS Crossing of the Blood-Brain Barrier Corrects CNS Defects in MPSII Mice

(2009) Vinicia Assunta Polito et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation

(2009) L E Polgreen et al.   BONE MARROW TRANSPLANTATION

Initial report from the Hunter Outcome Survey

(2009) J Edmond Wraith et al.   GENETICS IN MEDICINE

Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)

(2009) S. A. Jones et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy

(2009) Robert F. Wynn et al.   JOURNAL OF PEDIATRICS

Bone Marrow Transplantation in Children with Hunter Syndrome: Outcome after 7 to 17 Years

(2009) Nathalie Guffon et al.   JOURNAL OF PEDIATRICS

Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses

(2009) Barbara K. Burton et al.   MOLECULAR GENETICS AND METABOLISM

Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation

(2009) Ken Araya et al.   MOLECULAR GENETICS AND METABOLISM

Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)

(2009) Torayuki Okuyama et al.   MOLECULAR GENETICS AND METABOLISM

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts

(2009) Caterina Porto et al.   MOLECULAR THERAPY

Multidisciplinary Management of Hunter Syndrome

(2009) J. Muenzer et al.   PEDIATRICS

Mucopolysaccharidoses in Brazil: What happens from birth to biochemical diagnosis?

(2008) Taiane Vieira et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Home treatment with Elaprase® and Naglazyme® is safe in patients with mucopolysaccharidoses types II and VI, respectively

(2008) S. Bagewadi et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed

(2008) S. Al Sawaf et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Heparin cofactor II–thrombin complex: A biomarker of MPS disease

(2008) Derrick R. Randall et al.   MOLECULAR GENETICS AND METABOLISM

Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)

(2008) R. Martin et al.   PEDIATRICS